Literature DB >> 27351788

[Long-term glucocorticoid therapy : Is there a safe dosage?].

C Strehl1,2, F Buttgereit3,4.   

Abstract

Glucocorticoids have been successfully used for a long time to treat a wide range of chronic inflammatory diseases. Despite the well-accepted efficacy, possible adverse effects still provoke discussions among patients and physicians. In particular, the long-term use of glucocorticoids at higher dosages may cause unwanted adverse effects; therefore, the question arises if conditions for a safe long-term treatment regimen with these drugs can be defined. Studies specifically and comprehensively addressing this question are missing; therefore, a multidisciplinary task force comprised of medical experts and patients was formed to analyze and discuss the existing literature in order to identify conditions where long-term glucocorticoid treatment has an acceptably low level of harm. The group agreed that the actual level of harm of long-term glucocorticoid therapy depends on both drug (dose and duration) and patient-specific characteristics. The patient-specific parameters (some of which can be modified by patients and/or physicians) should always be monitored before and during treatment with glucocorticoids and optimized if necessary. A positive benefit-risk ratio can be achieved when current knowledge and existing recommendations are kept in mind and implemented in clinical practice.

Entities:  

Keywords:  Adverse events; Benefit-risk ratio; Patient specific factors; Rheumatoid arthritis; Risk factors

Mesh:

Substances:

Year:  2016        PMID: 27351788     DOI: 10.1007/s00108-016-0098-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  35 in total

1.  Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice.

Authors:  M C van der Goes; J W G Jacobs; M Boers; T Andrews; M A M Blom-Bakkers; F Buttgereit; N Caeyers; M Cutolo; J A P Da Silva; L Guillevin; J R Kirwan; J Rovensky; G Severijns; S Webber; R Westhovens; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2010-08-06       Impact factor: 19.103

2.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  J N Hoes; J W G Jacobs; M Boers; D Boumpas; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; G Esselens; L Guillevin; I Hafstrom; J R Kirwan; J Rovensky; A Russell; K G Saag; B Svensson; R Westhovens; H Zeidler; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

3.  Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study.

Authors:  Maurizio Mazzantini; Claudia Torre; Mario Miccoli; Angelo Baggiani; Rosaria Talarico; Stefano Bombardieri; Ombretta Di Munno
Journal:  J Rheumatol       Date:  2012-01-15       Impact factor: 4.666

4.  Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.

Authors:  Marije F Bakker; Johannes W G Jacobs; Paco M J Welsing; Suzanne M M Verstappen; Janneke Tekstra; Evelien Ton; Monique A W Geurts; Jacobine H van der Werf; Grietje A van Albada-Kuipers; Zalima N Jahangier-de Veen; Maaike J van der Veen; Catharina M Verhoef; Floris P J G Lafeber; Johannes W J Bijlsma
Journal:  Ann Intern Med       Date:  2012-03-06       Impact factor: 25.391

Review 5.  Use of oral corticosteroids and risk of fractures.

Authors:  T P Van Staa; H G Leufkens; L Abenhaim; B Zhang; C Cooper
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

Review 6.  Short-term and long-term safety of glucocorticoids in rheumatoid arthritis.

Authors:  Kenneth G Saag
Journal:  Bull NYU Hosp Jt Dis       Date:  2012

7.  Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  M C van der Goes; J W G Jacobs; M Boers; T Andrews; M A M Blom-Bakkers; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; L Guillevin; M Holland; J R Kirwan; J Rovensky; K G Saag; G Severijns; S Webber; R Westhovens; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2009-09-17       Impact factor: 19.103

Review 8.  When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations.

Authors:  Cécile Gaujoux-Viala; Laure Gossec
Journal:  Ann N Y Acad Sci       Date:  2014-05-14       Impact factor: 5.691

Review 9.  Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis.

Authors:  J N Hoes; J W G Jacobs; S M M Verstappen; J W J Bijlsma; G J M G Van der Heijden
Journal:  Ann Rheum Dis       Date:  2008-12-09       Impact factor: 19.103

10.  Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis.

Authors:  Mohammad Movahedi; Marie-Eve Beauchamp; Michal Abrahamowicz; David W Ray; Kaleb Michaud; Sofia Pedro; William G Dixon
Journal:  Arthritis Rheumatol       Date:  2016-05       Impact factor: 10.995

View more
  2 in total

1.  PA-Int5: An isatin-thiosemicarbazone derivative that exhibits anti-nociceptive and anti-inflammatory effects in Swiss mice.

Authors:  Aldilane Gonçalves Da Fonseca; Luzia Leiros De Sena Fernandes Ribeiro Dantas; Joquebede Pereira Rodrigues; Marco Polo Da Costa Alencar Filho; Moacyr Jesus Barreto De Melo Rêgo; Maira Galdino Da Rocha Pitta; Paulo André Teixeira De Moraes Gomes; Vanessa Gouveia De Melo Silva; Ana Cristina Lima Leite; Allanny Alves Furtado; Matheus De Freitas Fernandes Pedrosa; Elaine Cristina Gavioli; Telma Maria Araújo Moura Lemos
Journal:  Biomed Rep       Date:  2021-05-26

2.  Lipid, fatty acid, carnitine- and choline derivative profiles in rheumatoid arthritis outpatients with different degrees of periodontal inflammation.

Authors:  Kathrin Beyer; Stein Atle Lie; Bodil Bjørndal; Rolf K Berge; Asbjørn Svardal; Johan G Brun; Anne Isine Bolstad
Journal:  Sci Rep       Date:  2021-03-05       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.